Intuitive Surgical (NASDAQ:ISRG) Stock Unloaded Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Intuitive Surgical, Inc. (NASDAQ:ISRG). In a filing disclosed on February 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Intuitive Surgical stock on January 21st. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 1/30/2025.

Intuitive Surgical Trading Down 0.2 %

NASDAQ ISRG traded down $1.41 on Wednesday, reaching $590.24. 524,331 shares of the company were exchanged, compared to its average volume of 1,771,006. Intuitive Surgical, Inc. has a fifty-two week low of $364.17 and a fifty-two week high of $616.00. The stock has a market capitalization of $210.23 billion, a P/E ratio of 92.06, a price-to-earnings-growth ratio of 5.67 and a beta of 1.39. The business’s fifty day moving average price is $556.91 and its 200 day moving average price is $516.98.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ISRG shares. Mizuho boosted their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Bernstein Bank upped their price target on Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Piper Sandler restated an “overweight” rating and issued a $670.00 price objective (up from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. Citigroup increased their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Finally, Barclays upped their price objective on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Insiders Place Their Bets

In other news, EVP Myriam Curet sold 408 shares of Intuitive Surgical stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $589.75, for a total value of $240,618.00. Following the transaction, the executive vice president now directly owns 353 shares of the company’s stock, valued at $208,181.75. The trade was a 53.61 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,967,734. The trade was a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,348 shares of company stock valued at $3,587,582 over the last quarter. Company insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

Several hedge funds have recently added to or reduced their stakes in the stock. Atala Financial Inc acquired a new stake in Intuitive Surgical during the 4th quarter worth $25,000. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth about $26,000. BankPlus Trust Department purchased a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $28,000. Summit Securities Group LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $30,000. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Intuitive Surgical during the 4th quarter worth approximately $31,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.